Try our beta test site
11399 studies found for:    NCI
Show Display Options
Download search resultsDownload the search results for:
NCI (11399 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Not yet recruiting Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome
Conditions: Recurrent Mycosis Fungoides and Sezary Syndrome;   Refractory Mycosis Fungoides;   Stage IB Mycosis Fungoides and Sezary Syndrome;   Stage II Mycosis Fungoides and Sezary Syndrome;   Stage IIA Mycosis Fungoides and Sezary Syndrome;   Stage IIB Mycosis Fungoides and Sezary Syndrome;   Stage III Mycosis Fungoides and Sezary Syndrome;   Stage IIIA Mycosis Fungoides and Sezary Syndrome;   Stage IIIB Mycosis Fungoides and Sezary Syndrome;   Stage IV Mycosis Fungoides and Sezary Syndrome;   Stage IVA Mycosis Fungoides and Sezary Syndrome;   Stage IVB Mycosis Fungoides and Sezary Syndrome
Interventions: Biological: Interferon Gamma-1b;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
2 Not yet recruiting Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast
Condition: Mammographically Dense Breast
Interventions: Drug: Afimoxifene;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Questionnaire Administration
3 Recruiting Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
Conditions: Sarcomatoid Renal Cell Carcinoma;   Stage II Renal Cell Cancer;   Stage III Renal Cell Cancer;   Unclassified Renal Cell Carcinoma
Interventions: Procedure: Conventional Surgery;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Patient Observation;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
4 Recruiting Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
Conditions: Metastatic Transitional Cell Carcinoma;   Metastatic Urothelial Carcinoma;   Recurrent Bladder Carcinoma;   Stage III Bladder Urothelial Carcinoma;   Stage IV Bladder Urothelial Carcinoma;   TSC1 Gene Mutation;   TSC2 Gene Mutation
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Sapanisertib
5 Not yet recruiting MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia
Conditions: Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   TP53 wt Allele;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Drug: MDM2 Inhibitor AMG-232;   Other: Pharmacological Study
6 Not yet recruiting Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations
Conditions: KRAS NP_004976.2:p.G12R;   Stage II Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Selumetinib Sulfate
7 Not yet recruiting Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
Conditions: Activated B-Cell-Like Diffuse Large B-Cell Lymphoma;   ALK-Positive Large B-Cell Lymphoma;   Atypical Burkitt/Burkitt-Like Lymphoma;   Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma of the Elderly;   Epstein-Barr Virus-Positive Mucocutaneous Ulcer;   Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma;   High-Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements;   Human Herpesvirus-8-Positive Neoplastic Cells Present;   Intravascular Large B-Cell Lymphoma;   MYC-Negative B-Cell Lymphoma With 11q Aberration Resembling Burkitt Lymphoma;   Plasmablastic Lymphoma;   Primary Cutaneous Diffuse Large B-Cell Lymphoma;   Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type;   Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System;   Primary Effusion Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Lymphomatoid Granulomatosis;   Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Skin Ulcer;   Small Intestinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Varlilumab
8 Not yet recruiting Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papillomavirus-Related Cancer in Adult Women After Kidney Transplant
Condition: Solid Organ Transplantation Recipient
Interventions: Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Biological: Recombinant Human Papillomavirus Nonavalent Vaccine
9 Not yet recruiting Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery
Conditions: Stage III Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
10 Not yet recruiting MDM2 Inhibitor AMG-232, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Hypercalcemia;   Plasmacytoma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Drug: Carfilzomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: MDM2 Inhibitor AMG-232;   Other: Pharmacological Study
11 Not yet recruiting Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
Conditions: Metastatic Malignant Solid Neoplasm;   Unresectable Solid Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Biological: Recombinant Interleukin-12
12 Not yet recruiting Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
Conditions: Grade 1 Endometrial Endometrioid Adenocarcinoma;   Grade 2 Endometrial Endometrioid Adenocarcinoma;   Grade 3 Endometrial Endometrioid Adenocarcinoma;   Uterine Corpus Adenosarcoma
Interventions: Drug: Entinostat;   Procedure: Hysterectomy;   Other: Laboratory Biomarker Analysis;   Drug: Medroxyprogesterone Acetate
13 Not yet recruiting Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Metastatic Malignant Neoplasm in the Lymph Nodes;   Recurrent Gastric Carcinoma;   Stage IV Gastric Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Other: Quality-of-Life Assessment;   Biological: Ramucirumab
14 Not yet recruiting Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer
Conditions: Colorectal Adenocarcinoma;   High-Frequency Microsatellite Instability;   Stage IV Colorectal Cancer;   Stage IVA Colorectal Cancer;   Stage IVB Colorectal Cancer
Interventions: Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
15 Not yet recruiting Tamoxifen Citrate or Afimoxifene in Treating Patients With Estrogen Receptor Positive Breast Cancer
Conditions: Ductal Breast Carcinoma In Situ;   Estrogen Receptor Positive
Interventions: Drug: Afimoxifene;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Drug: Tamoxifen Citrate
16 Recruiting Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
Conditions: Metastatic Malignant Neoplasm;   Metastatic Malignant Neoplasm in the Brain
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Drug: Ropidoxuridine;   Radiation: Whole-Brain Radiotherapy
17 Not yet recruiting Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Conditions: Adenoid Cystic Carcinoma;   Adnexal Carcinoma;   Apocrine Carcinoma;   Eccrine Porocarcinoma;   Extraocular Cutaneous Sebaceous Carcinoma;   Hidradenocarcinoma;   Keratoacanthoma;   Malignant Sweat Gland Neoplasm;   Merkel Cell Carcinoma;   Microcystic Adnexal Carcinoma;   NK-Cell Lymphoma, Unclassifiable;   Non-Melanomatous Lesion;   Paget Disease;   Papillary Adenocarcinoma;   Primary Cutaneous Mucinous Carcinoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Refractory T-Cell Non-Hodgkin Lymphoma;   Sezary Syndrome;   Signet Ring Cell Carcinoma;   Skin Basal Cell Carcinoma;   Skin Basosquamous Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Spiradenocarcinoma;   Squamous Cell Carcinoma of Unknown Primary Origin;   Stage III Skin Cancer;   Stage IV Skin Cancer;   Sweat Gland Carcinoma;   Trichilemmocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Talimogene Laherparepvec
18 Not yet recruiting Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
Condition: Recurrent Glioblastoma
Interventions: Biological: Bevacizumab;   Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib
19 Not yet recruiting Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
Conditions: EGFR Activating Mutation;   EGFR NP_005219.2:p.T790M;   Metastatic Malignant Neoplasm in the Brain;   Non-Small Cell Lung Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma
Interventions: Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Osimertinib
20 Not yet recruiting Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis
Condition: Cirrhosis
Interventions: Other: Laboratory Biomarker Analysis;   Other: Placebo;   Drug: Simvastatin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.